Fluxion Biosciences announced that it has won a 2013 R&D 100 Award for its IsoFlux system. The R&D 100 Award places the state-of-the-art IsoFlux system in the prestigious company of previous winners such as liquid crystal displays and the anticancer drug Taxol.
Known as "the Oscars of Innovation", the R&D 100 Award showcases the most significant new technologies worldwide. This year, R&D Magazine recognized Fluxion’s IsoFlux system for its ability to perform a “liquid biopsy” on a cancer patient by analyzing a patient’s cancer markers from a simple blood draw. Based on Fluxion’s novel microfluidics, the IsoFlux system isolates, purifies and recovers cancer cells at levels that weren’t previously possible. Complete analytical workflows are available to detect genomic mutations, gene expression profiles, protein expression and chromosomal abnormalities.
Introduced in 2012, the IsoFlux system is used globally by drug developers and cancer research institutes including Bayer, Ingham Institute, Univ. of Dusseldorf, Stanford Univ. and others. The system is being used for a number of applications, including clinical trial patient testing, longitudinal monitoring of patients during treatment and as a replacement for tissue in hard-to-biopsy cancers such as lung and pancreas.
Source: Fluxion Biosciences